ID   KYSE-50
AC   CVCL_1360
AS   CVCL_9821
SY   KYSE 50; KYSE50; KY-50
DR   CLO; CLO_0009934
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03471649
DR   cancercelllines; CVCL_1360
DR   Cell_Model_Passport; SIDM00550
DR   Cosmic; 918522
DR   Cosmic; 929520
DR   Cosmic; 1043238
DR   Cosmic; 1123334
DR   Cosmic; 1581069
DR   Cosmic; 1876250
DR   Cosmic; 1995477
DR   Cosmic; 2395006
DR   Cosmic; 2650628
DR   Cosmic-CLP; 1298222
DR   DepMap; ACH-002264
DR   EGA; EGAS00001000978
DR   GDSC; 1298222
DR   GEO; GSM827503
DR   GEO; GSM1670023
DR   JCRB; JCRB0189
DR   LINCS_LDP; LCL-1560
DR   PharmacoDB; KYSE50_809_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1360
DR   Wikidata; Q54900832
RX   PubMed=1728357;
RX   PubMed=7913084;
RX   PubMed=9033652;
RX   PubMed=20215515;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 28.2 hours (PubMed=1728357); ~2-3 days (Note=Lot 02182005) (JCRB=JCRB0189).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Glu539Ter (c.1615G>T); Zygosity=Homozygous (Cosmic-CLP=1298222; DepMap=ACH-002264).
CC   Sequence variation: Mutation; HGNC; 667; RHOA; Simple; p.Gly17Val (c.50G>T); Zygosity=Heterozygous (Cosmic-CLP=1298222; DepMap=ACH-002264).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys101Ter (c.301A>T); Zygosity=Homozygous (Cosmic-CLP=1298222; DepMap=ACH-002264).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.31%; Native American=0%; East Asian, North=73.2%; East Asian, South=24.47%; South Asian=2.01%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Derived from site: In situ; Esophagus; UBERON=UBERON_0001043.
ST   Source(s): Cosmic-CLP=1298222; JCRB=JCRB0189
ST   Amelogenin: X
ST   CSF1PO: 11,12 (JCRB=JCRB0189)
ST   CSF1PO: 12 (Cosmic-CLP=1298222)
ST   D13S317: 11
ST   D16S539: 10,12
ST   D5S818: 11
ST   D7S820: 10
ST   TH01: 8
ST   TPOX: 11
ST   vWA: 17,19
DI   NCIt; C4024; Esophageal squamous cell carcinoma
DI   ORDO; Orphanet_99977; Squamous cell carcinoma of the esophagus
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 35
//
RX   PubMed=1728357; DOI=10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C;
RA   Shimada Y., Imamura M., Wagata T., Yamaguchi N., Tobe T.;
RT   "Characterization of 21 newly established esophageal cancer cell
RT   lines.";
RL   Cancer 69:277-284(1992).
//
RX   PubMed=7913084; DOI=10.1002/ijc.2910580224;
RA   Kanda Y., Nishiyama Y., Shimada Y., Imamura M., Nomura H., Hiai H.,
RA   Fukumoto M.;
RT   "Analysis of gene amplification and overexpression in human
RT   esophageal-carcinoma cell lines.";
RL   Int. J. Cancer 58:291-297(1994).
//
RX   PubMed=9033652; DOI=10.1002/(SICI)1097-0215(19970207)70:4<437::AID-IJC11>3.0.CO;2-C;
RA   Tanaka H., Shimada Y., Imamura M., Shibagaki I., Ishizaki K.;
RT   "Multiple types of aberrations in the p16 (INK4a) and the p15(INK4b)
RT   genes in 30 esophageal squamous-cell-carcinoma cell lines.";
RL   Int. J. Cancer 70:437-442(1997).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//